Brokers Offer Predictions for ORIC FY2026 Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for ORIC Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($2.15) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for ORIC Pharmaceuticals' current full-year earnings is ($2.17) per share.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.09.

Several other analysts have also issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a "buy" rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a research note on Monday, May 5th. Wedbush reaffirmed an "outperform" rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research note on Thursday, May 29th. Oppenheimer decreased their target price on shares of ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Finally, Guggenheim reaffirmed a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $19.17.

ORIC Pharmaceuticals Price Performance

NASDAQ ORIC traded down $0.04 during trading on Wednesday, hitting $9.63. 714,124 shares of the company's stock traded hands, compared to its average volume of 775,451. The stock has a fifty day moving average of $6.15 and a two-hundred day moving average of $7.69. ORIC Pharmaceuticals has a 12-month low of $3.90 and a 12-month high of $14.67. The firm has a market cap of $820.71 million, a P/E ratio of -5.29 and a beta of 1.49.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORIC. Bank of America Corp DE raised its stake in ORIC Pharmaceuticals by 34.0% during the 4th quarter. Bank of America Corp DE now owns 112,520 shares of the company's stock valued at $908,000 after buying an additional 28,570 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of ORIC Pharmaceuticals by 16.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 717,188 shares of the company's stock worth $5,788,000 after acquiring an additional 103,237 shares during the period. Wellington Management Group LLP grew its holdings in shares of ORIC Pharmaceuticals by 6.9% in the fourth quarter. Wellington Management Group LLP now owns 186,430 shares of the company's stock worth $1,504,000 after acquiring an additional 12,042 shares during the period. Sphera Funds Management LTD. increased its position in ORIC Pharmaceuticals by 112.8% during the fourth quarter. Sphera Funds Management LTD. now owns 273,213 shares of the company's stock valued at $2,205,000 after acquiring an additional 144,817 shares during the last quarter. Finally, Diadema Partners LP bought a new position in ORIC Pharmaceuticals in the fourth quarter valued at about $1,729,000. Institutional investors own 95.05% of the company's stock.

Insiders Place Their Bets

In other news, CFO Dominic Piscitelli sold 2,976 shares of ORIC Pharmaceuticals stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $10.01, for a total value of $29,789.76. Following the completion of the sale, the chief financial officer now directly owns 102,117 shares in the company, valued at $1,022,191.17. The trade was a 2.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders sold 6,500 shares of company stock valued at $65,056. 6.82% of the stock is owned by insiders.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.